Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Actinium issued a press release on August 5, 2024, “announc[ing] a regulatory update on the Company’s planned Biologics License Application (‘BLA’) filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML’).” The press release stated, in relevant part, that the U.S. Food And Drug Administration had “determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint[.]”
Following this news, Actinium’s stock price fell over 59% the same day.
| Ticker Symbol | Company Name | Join Deadline | |
|---|---|---|---|
| GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
| NEM | Newmont Corporation | April 01, 2025 | Join |
| GSK | GSK plc | April 07, 2025 | Join |
| NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
| MRK | Merck & Co., Inc. | April 14, 2025 | Join |
| VG | Venture Global, Inc. | April 18, 2025 | Join |
| STZ | Constellation Brands, Inc. | April 21, 2025 | Join |
| SWKS | Skyworks Solutions, Inc. | May 05, 2025 | Join |
| SWKS | Skyworks Solutions, Inc. | May 05, 2025 | Join |